Enliven Therapeutics (ELVN) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Enliven Therapeutics (ELVN) over the past year, gaining 116.7% versus a gain of 113.9%. Over five years, ELVN leads with a +254.6% price change compared with +110.0% for TNGX. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.42 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | TNGX |
|---|---|---|
| Share price | $46.53 | $21.73 |
| Market cap | $3.42B | $3.68B |
| 1-day change | +0.26% | -4.32% |
| YTD return | +202.14% | +145.26% |
| 1-year return | +113.93% | +116.65% |
| 5-year return | +254.65% | +109.95% |
| EPS (TTM) | $-1.69 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $62.38M |
| Revenue growth (YoY) | — | +48.29% |
| Net income (latest FY) | $-103.69M | $-101.59M |
| Operating margin | — | -178.39% |
| Net margin | — | -162.85% |
| 52-week high | $62.32 | $34.39 |
| 52-week low | $14.79 | $8.30 |
| Distance from 52-week high | -25.34% | -36.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +59.75% | +116.29% |
| Average volume | 1.36M | 3.41M |
| Shares outstanding | 73.60M | 169.46M |
| Employees | 65 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
ELVN vs TNGX FAQ
Which is bigger, Enliven Therapeutics or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.42B for Enliven Therapeutics (ELVN).
Which stock has performed better over the past year, ELVN or TNGX?
TNGX returned +116.65% over the past 12 months, compared with +113.93% for ELVN (price return, excluding dividends). Past performance does not predict future results.
Are Enliven Therapeutics and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.